Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Current Leases (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Current Leases for 4 consecutive years, with $648000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 29.34% to $648000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $648000.0, a 29.34% increase, with the full-year FY2025 number at $648000.0, up 29.34% from a year prior.
  • Current Leases was $648000.0 for Q4 2025 at Phathom Pharmaceuticals, up from $591000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $730000.0 in Q1 2024 to a low of $238000.0 in Q2 2025.
  • A 4-year average of $581333.3 and a median of $638000.0 in 2022 define the central range for Current Leases.
  • Biggest YoY gain for Current Leases was 29.34% in 2025; the steepest drop was 66.94% in 2025.
  • Phathom Pharmaceuticals' Current Leases stood at $708000.0 in 2022, then rose by 2.54% to $726000.0 in 2023, then crashed by 30.99% to $501000.0 in 2024, then increased by 29.34% to $648000.0 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Current Leases are $648000.0 (Q4 2025), $591000.0 (Q3 2025), and $238000.0 (Q2 2025).